Skip to main content
Top
Published in: Clinical and Experimental Medicine 4/2012

01-12-2012 | Original Article

Establishment of an experimental method for detecting circulating miRNAs in BDL mice

Authors: Shuangshuang Yang, Yan Wu, Danni Wang, Shifeng Huang, Yangan Wen, Ju Cao, Liping Zhang

Published in: Clinical and Experimental Medicine | Issue 4/2012

Login to get access

Abstract

Despite its great potency in self-rehabilitation, liver is the most vulnerable organ, and an early minor liver injury is unfortunately undetectable by the traditional assay of aminotransferases; hence, more sensitive and specific biomarkers of minor liver injury have attracted much attention. A number of studies have suggested that circulating microRNAs (miRNAs) are accessible and attractive parameters of early tissue injury. A recent study has found that plasma microRNA-122 is a disease severity-dependent biomarker, and there is an elevated level of microRNA-122 prior to the alteration of aminotransferases in viral, alcohol, and chemical-related hepatic injuries. Since bile duct-ligated (BDL) mice have been well adapted as an effective model of cholestatic hepatic injury, liver fibrosis, liver cirrhosis, and their relevant complications, we hypothesized that detection of circulating miRNAs will probably find its unique utility in BDL model and thus exploited an effective and reliable experimental method of studying serum-based miRNAs in BDL mice.
Literature
1.
go back to reference Hosoda T, Zheng H, Cabral-da-Silva M et al (2011) Human cardiac stem cell differentiation is regulated by a mircrine mechanism. Circulation 123:1287–1296PubMedCrossRef Hosoda T, Zheng H, Cabral-da-Silva M et al (2011) Human cardiac stem cell differentiation is regulated by a mircrine mechanism. Circulation 123:1287–1296PubMedCrossRef
2.
go back to reference Allendorf DJ, Davis RS (2011) Unraveling the molecular pathogenesis of chronic lymphocytic leukemia: dissecting a microRNA regulatory network. JAMA 305:95–97PubMedCrossRef Allendorf DJ, Davis RS (2011) Unraveling the molecular pathogenesis of chronic lymphocytic leukemia: dissecting a microRNA regulatory network. JAMA 305:95–97PubMedCrossRef
4.
go back to reference Laterza OF, Lim L, Garrett-Engele PW et al (2009) Plasma microRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem 55:1977–1983PubMedCrossRef Laterza OF, Lim L, Garrett-Engele PW et al (2009) Plasma microRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem 55:1977–1983PubMedCrossRef
5.
go back to reference Funahashi H, Izawa H, Hirashiki A et al (2011) Altered microRNA expression associated with reduced catecholamine sensitivity in patients with chronic heart failure. J Cardiol 57:338–344PubMedCrossRef Funahashi H, Izawa H, Hirashiki A et al (2011) Altered microRNA expression associated with reduced catecholamine sensitivity in patients with chronic heart failure. J Cardiol 57:338–344PubMedCrossRef
6.
go back to reference Chen X, Ba Y, Ma L et al (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18:997–1006PubMedCrossRef Chen X, Ba Y, Ma L et al (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18:997–1006PubMedCrossRef
7.
go back to reference Wang G, Tam L, Li E et al (2011) Serum and urinary free microRNA level in patients with systemic lupus erythematosus. Lupus 20:493–500PubMedCrossRef Wang G, Tam L, Li E et al (2011) Serum and urinary free microRNA level in patients with systemic lupus erythematosus. Lupus 20:493–500PubMedCrossRef
8.
go back to reference Schöler N, Langer C, Döhner H et al (2010) Serum microRNAs as a novel class of biomarkers: a comprehensive review of the literature. Exp Hematol 38:1126–1130PubMedCrossRef Schöler N, Langer C, Döhner H et al (2010) Serum microRNAs as a novel class of biomarkers: a comprehensive review of the literature. Exp Hematol 38:1126–1130PubMedCrossRef
9.
go back to reference Zhang Y, Jia Y, Zheng R et al (2010) Plasma microRNA-122 as a biomarker for viral-, alcohol- and chemical-related hepatic diseases. Clin Chem 56:1830–1838PubMedCrossRef Zhang Y, Jia Y, Zheng R et al (2010) Plasma microRNA-122 as a biomarker for viral-, alcohol- and chemical-related hepatic diseases. Clin Chem 56:1830–1838PubMedCrossRef
10.
go back to reference Wang K, Zhang S, Marzolf B et al (2009) Circulating microRNAs, potential biomarkers for drug-induced liver injury. PNAS 106:4402–4407PubMedCrossRef Wang K, Zhang S, Marzolf B et al (2009) Circulating microRNAs, potential biomarkers for drug-induced liver injury. PNAS 106:4402–4407PubMedCrossRef
11.
go back to reference Uchinami H, Seki E, Brenner DA et al (2006) Loss of MMP13 attenuates murine hepatic injury and fibrosis during cholestasis. Hepatology 44:420–429PubMedCrossRef Uchinami H, Seki E, Brenner DA et al (2006) Loss of MMP13 attenuates murine hepatic injury and fibrosis during cholestasis. Hepatology 44:420–429PubMedCrossRef
12.
go back to reference Mitchell PS, Parkin RK, Kroh EM et al (2008) Circulating microRNAs as stable blood-based markers for cancer detection. PNAS 105:10513–10518PubMedCrossRef Mitchell PS, Parkin RK, Kroh EM et al (2008) Circulating microRNAs as stable blood-based markers for cancer detection. PNAS 105:10513–10518PubMedCrossRef
13.
go back to reference Guo CJ, Pan Q, Jiang B et al (2009) Effects of upregulated expression of microRNA-16 on biological properties of culture-activated hepatic stellate cells. Apoptosis 4:1331–1340CrossRef Guo CJ, Pan Q, Jiang B et al (2009) Effects of upregulated expression of microRNA-16 on biological properties of culture-activated hepatic stellate cells. Apoptosis 4:1331–1340CrossRef
14.
go back to reference Liu Q, Hanjiang F, Sun F et al (2008) MiR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. Nucleic Acids Res 36:5391–5404PubMedCrossRef Liu Q, Hanjiang F, Sun F et al (2008) MiR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. Nucleic Acids Res 36:5391–5404PubMedCrossRef
15.
go back to reference Kroh EM, Parkin RK, Mitchell PS (2010) Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 50:298–301PubMedCrossRef Kroh EM, Parkin RK, Mitchell PS (2010) Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 50:298–301PubMedCrossRef
16.
go back to reference McDonald JS, Milosevic D, Reddi HV et al (2011) Analysis of circulating MicroRNA: preanalytical and analytical challenges. Clin Chem 57:833–840PubMedCrossRef McDonald JS, Milosevic D, Reddi HV et al (2011) Analysis of circulating MicroRNA: preanalytical and analytical challenges. Clin Chem 57:833–840PubMedCrossRef
17.
go back to reference Arroyo JD, Chevillet JR, Kroh EM et al (2011) Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. PNAS 108:5003–5008PubMedCrossRef Arroyo JD, Chevillet JR, Kroh EM et al (2011) Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. PNAS 108:5003–5008PubMedCrossRef
Metadata
Title
Establishment of an experimental method for detecting circulating miRNAs in BDL mice
Authors
Shuangshuang Yang
Yan Wu
Danni Wang
Shifeng Huang
Yangan Wen
Ju Cao
Liping Zhang
Publication date
01-12-2012
Publisher
Springer Milan
Published in
Clinical and Experimental Medicine / Issue 4/2012
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-011-0168-z

Other articles of this Issue 4/2012

Clinical and Experimental Medicine 4/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.